Mahavir Laboratories Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.15 M
- Company Age 16 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -41.80%
- Profit Growth 42.42%
- Ebitda 18.54%
- Net Worth 10.93%
- Total Assets -25.19%
About Mahavir Laboratories
Mahavir Laboratories Private Limited (MLPL) is a Private Limited Indian Non-Government Company incorporated in India on 19 May 2008 and has a history of 16 years and eight months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.15 M, as per Ministry of Corporate Affairs (MCA) records.
Arun Sehgal and Vijay Agarwal serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U24230MH2008PTC182429
-
Company No.
182429
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
19 May 2008
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Mahavir Laboratories?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arun Sehgal
|
Director | 19-May-2008 | Current |
|
Vijay Agarwal
|
Director | 19-May-2008 | Current |
Financial Performance of Mahavir Laboratories.
Mahavir Laboratories Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 41.8% decrease. The company also saw a substantial improvement in profitability, with a 42.42% increase in profit. The company's net worth Soared by an impressive increase of 10.93%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mahavir Laboratories?
In 2019, Mahavir Laboratories had a promoter holding of 66.67% and a public holding of 33.33%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Chempro Pharma Private LimitedArun Sehgal and Vijay Agarwal are mutual person
-
Goldstar Chemicals Private LimitedArun Sehgal and Vijay Agarwal are mutual person
-
Jbims Alumni AssociationArun Sehgal is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Mahavir Laboratories?
Unlock and access historical data on people associated with Mahavir Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mahavir Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mahavir Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.